about
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse eventsFibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices.Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression.Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessSystemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary DiseaseStudy of breast cancer incidence in patients of lymphangioleiomyomatosis.Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAngiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages.Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.Treatment Considerations of Lung Involvement in Rheumatologic Disease.Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis.Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain.Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis.Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countriesErratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices.[Adult pulmonary Langerhans' cell histiocytosis: approach to the reality of the Spanish population].Preclinical lung disease in early rheumatoid arthritis.Towards a global initiative for fibrosis treatment (GIFT).Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis.The JAK2 pathway is activated in idiopathic pulmonary fibrosis.Guidelines for the medical treatment of idiopathic pulmonary fibrosis.Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosisDemographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry.[Airway-centered interstitial fibrosis related to exposure to fumes from cleaning products][Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis][Experimental models for the study of pulmonary fibrosis: current usefulness and future promise][Transbronchial needle aspiration in the study of mediastinal lymph nodes: yield and cost-effectiveness][Diffuse interstitial lung disease related to peribronchiolar metaplasia][Laryngeal tuberculosis and coadjuvant corticosteroid treatment]Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunctionGene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD PatientsEuropean idiopathic pulmonary fibrosis Patient Charter: a missed opportunity[Lymphoproliferative pulmonary infiltration: A diagnosis to keep in mind in pulmonary infiltrates in patient with chronic lymphocytic leukemia]Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data
P50
Q26824810-B135375E-52BA-4D8A-A68A-385F9B415FB3Q30656978-BEAB5A5C-3AA6-42EC-B900-088528E8F42BQ34010640-7BFEE47D-13F2-4E93-9396-F5D3C809C387Q34766530-A03B4D14-7452-4B97-82B2-0FFB2C6068A7Q35663920-F1797755-F2FB-46D9-850F-A534C731E28CQ35689467-C8B1630A-D14C-4EB2-A10D-2F636B681F99Q35980048-7CFB0895-463E-409A-8885-769BF6A1C4D7Q36678521-4BDCCA33-1D7A-4E02-8C38-279527A44E9AQ36808001-15CF1053-8F8E-44A9-813E-A555E83EEEBBQ36822922-1427E467-CEE2-4B46-B5BF-5A199FBEEEC1Q37726793-F0757E68-FBED-4330-93D8-51ED54926632Q38605943-90680697-EE26-418F-BC39-8132B246FC00Q39253039-D4F1BCB8-30BC-4804-8AE6-CDE052C63994Q40116548-987FA2B9-63D2-46FF-87AB-3DB674AB1FF9Q40255180-98FC59B6-CC16-4C2D-A11C-79F1489011C1Q40501212-D58D6F95-6D5D-4E29-BAB3-D2E92D030CBEQ41712176-826BEE73-D845-4315-9BEF-BCFFEFADBB9DQ43191239-CC046B17-5F6A-4861-9B98-C6008D6B41D0Q44760790-C4D390FB-5064-4E0B-9BB9-4B07648D7284Q47096098-495B0D9C-D1AE-4298-A976-5EE90DE1ED50Q47152449-ED80BD2C-0C41-4195-9B36-3CE3C8D0DC68Q47766194-F11106ED-A278-4E9E-8B05-885A2CED7A7FQ48509995-2894D738-2AC7-4A5E-A3C8-D5A55A572907Q48683152-848E3BBF-C993-45A7-8FF9-355796F876BCQ49960065-C2237A47-859E-434D-AE07-9838492FD0BBQ50056514-0637AB65-189D-4887-BF7B-14F09F082549Q50277461-9A811A45-32A8-446F-A83B-771E387524E3Q57465979-35E05F64-CB17-4BEF-A029-C89A93CE3512Q64879863-FD6BF3D6-437B-4CF7-AB31-9ED2F8216C1EQ79305365-ABA5AFD8-C4F7-4608-A4C4-739C24ADF791Q80203952-C9C453E9-14C6-455B-86F9-7C2A8E88FC59Q81403395-1E08E745-93BE-450F-BEF3-6314BC27B328Q81468562-DB65A08D-E497-4A77-A985-3AA28586F6BDQ83279801-B963034C-DF82-4CAE-A9A4-B78F5050AE9AQ86367411-B0C8A69F-1DD3-409C-B2F9-4696BEFD6FDDQ86901969-3D89AD76-22C8-458E-B115-0B490B37D70EQ86967025-13002C42-082F-48E1-80E9-5157613D201AQ87793366-51140F08-2A25-49E2-AD01-041A74517E93Q89207109-618AA2EB-CC52-4B06-8DC5-62B8B9EF6455Q90209580-B6F66870-F54D-4696-97CD-0E6CE0AE022F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
María Molina-Molina
@en
María Molina-Molina
@nl
type
label
María Molina-Molina
@en
María Molina-Molina
@nl
prefLabel
María Molina-Molina
@en
María Molina-Molina
@nl
P31
P496
0000-0002-1852-1723